DT120 delivered a Phase 3 surprise. Can Definium Therapeutics turn $805m into a launch?
Definium Therapeutics has used the strong market response to its DT120 ODT depression data to secure one of the largest recent biotechnology financings, giving the psychiatric drug developer substantial resources for additional trials, regulatory work and potential commercialisation.